Small Molecule: News & Recent Developments
Nov 04, 2024 Journey Medical’s Emrosi, a small-molecule treatment for rosacea, receives FDA approval. (Source) Viking Therapeutics announces positive Phase 1 results for its novel small-molecule obesity treatment. (Source) Formosa Pharmaceuticals reports positive Phase 3 trial results for APP13007, a small molecule drug designed to reduce inflammation and pain after cataract surgery in Chinese patients. […]
Lipid nanoparticles (LNPs): Delivering Therapeutics / Drug Formulations
Lipid nanoparticles (LNPs) are a class of nanocarriers that have gained significant attention in recent years due to their ability to effectively deliver various therapeutic molecules, including mRNA, siRNA, and small molecules. These particles are composed of lipid-based components, such as phospholipids, cholesterol, and helper lipids, which self-assemble into spherical structures. Key Advantages of LNPs: […]
Microbiome Therapeutics: News & Recent Developments
Oct 09, 2024 Holobiome Secures Seed Funding. (Source) About “Microbiome Therapeutics” Microbiome therapeutics is a rapidly evolving field that focuses on harnessing the power of the human microbiome to treat diseases. The microbiome, consisting of trillions of microorganisms (bacteria, fungi, viruses, and others), plays a crucial role in various bodily functions, including digestion, immunity, and […]
Antibody-drug conjugate: News & Recent Developments
Nov 04, 2024 CrossBridge Bio Secures $10M Investment to Revolutionize Cancer Treatment with Dual-Payload ADCs. (Source) BigHat Biosciences teams up with Synaffix to develop next-generation antibody-drug conjugates (ADCs) using cutting-edge platform technology and drug discovery techniques. Antibody-drug conjuugate, platform tech, drug discovery (Source) Oct 24, 2024 ABL Bio and IntoCell Join Forces to Develop Innovative […]
Autologous TCR: News & Recent Developments
Oct 10, 2024 Immatics Reports Positive Phase 1b Data for ACTengine® IMA203, a PRAME-Targeting TCR-T Cell Therapy, in Patients with Metastatic Melanoma, and Provides Details on the Upcoming SUPRAME Phase 3 Trial. (Source) About “Autologous T-Cell Receptors (TCRs)” Autologous TCRs (T-Cell Receptors) are a type of immunotherapy that harnesses the patient’s own immune system to […]
Monoclonal Antibody: News & Recent Developments
Oct 24, 2024 Hope Medicine’s mAb HMI-115 shows promise in treating endometriosis pain. (Source) Merck’s KEYTRUDA® (pembrolizumab) Receives 30th European Commission Approval, Expanding Treatment Options for Gynecologic Cancers. (Source) Regeneron’s Dupixent Targets Chronic Urticaria with Monoclonal Antibody Therapy. (Source) Oct 23, 2024 Calluna Pharma advances novel fibrotic and fibro-inflammatory therapy, CAL101, to Phase 2 trials […]
Antisense Oligonucleotide: News & Recent Developments
Oct 16, 2024 AstraZeneca and Ionis’s Wainzua (eplontersen) approved by UK MHRA for ATTRv polyneuropathy. Antisense oligonucleotide, polyneuropathy associated with hereditary transthyretin amyloidosis (Source) Takeda has decided to terminate its partnership with Wave Life Sciences after investing a significant sum of $260 million in the collaborative effort. Antisense oligonucleotide, Huntington’s disease (Source) Oct 10, 2024 […]